We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases PR Newswire CAMBRIDGE, Mass., April 29...
Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy...
U.S. index futures fell in pre-market trading on Thursday, particularly technology stocks, which saw a significant depreciation after Meta Platforms (NASDAQ:META) announced disheartening...
Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange...
Apple (NASDAQ:AAPL) – Smartphone shipments from Apple in China fell 19% in the first quarter due to competition from Huawei. Its market share decreased to 15.7%, nearly matching that of...
Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale...
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting...
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients...
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -4.86 | -9.89816700611 | 49.1 | 49.1 | 43.728 | 23318260 | 45.17597788 | CS |
4 | -8.51 | -16.1327014218 | 52.75 | 52.87 | 43.728 | 13883236 | 47.75766682 | CS |
12 | -4.96 | -10.081300813 | 49.2 | 55.035 | 43.728 | 15848310 | 50.51400244 | CS |
26 | -7.62 | -14.693405322 | 51.86 | 55.035 | 43.728 | 15650343 | 50.51482937 | CS |
52 | -23.04 | -34.2449464923 | 67.28 | 69.1 | 43.728 | 12977243 | 54.84383507 | CS |
156 | -18.53 | -29.5204715628 | 62.77 | 81.435 | 43.728 | 11577002 | 63.62151407 | CS |
260 | -2.08 | -4.49050086356 | 46.32 | 81.435 | 41.19 | 12299671 | 60.94564833 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions